Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Lilly

Eli Lilly Is Bringing AI-Developed Drugs to Market. Should You Buy LLY Stock to Profit?

Eli Lilly has expanded its partnership with Insilico Medicine to bring AI developed medicine into global market.

Barchart

Eli Lilly invests in AI-designed drugs in new deal with Insilico Medicine worth up to €2.39bn

Eli Lilly has partnered with AI biotech Insilico Medicine for exclusive global rights to develop and commercialise medicines designed entirely by artificial intelligence.

Euronews

NHS watchdog to review evidence on two pioneering Alzheimer’s drugs

Donanemab and lecanemab were licensed for use in the UK in 2024 but were not made available on the NHS after Nice deemed their benefits “too small” to justify the cost

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Ireland courts U.S. companies as taoiseach brings deals to Trump on St. Patrick's Day

Pharma exports helped double Ireland’s goods trade surplus with the U.S. to $114 billion last year.

Fortune

Eli Lilly’s Employer Push Could Unlock New GLP-1 Demand

Eli Lilly is launching Employer Connect to expand Zepbound access while its oral GLP-1 orforglipron just topped Novo Nordisk's Rybelsus in a head-to-head trial.

MarketBeat

The Real Reason Eli Lilly Is Pouring $3 Billion Into China

Eli Lilly's major investment in China's manufacturing capacity is a strategic move to secure its supply chain and capture a vast, untapped growth market.

MarketBeat

Beyond the Slopes: Mikaela Shiffrin’s Mission to Help Educate Families Facing Early Symptomatic Alzheimer’s Disease

Mikaela was compensated for her time by Eli Lilly and Company. The Most Decorated Skier of Our Time Mikaela Shiffrin knows what it means to chase down a challen

Sports Illustrated

Read news from The Economist, FT, and more,
with one subscription

Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

Barchart

Novo Nordisk Stock Is Deeply Oversold on Weight Loss Drug Fail. Should You Buy the Dip?

Novo Nordisk stock tanks as CagriSema appears inferior to Eli Lilly’s competing weight-loss drug in a late-stage trial. But NVO shares are still worth buying at current levels.

Barchart

Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is labelled ‘obsolete’

Novo Nordisk’s shares fall sharply after testing of CagriSema falls short of investors’ expectations

The Guardian - UK

Weight-loss race: how switch from injections to pills is expanding big pharma’s hopes

Tablets could make treatment more mainstream, with sector predicted to be worth $200bn by end of the decade

The Guardian - UK

Eli Lilly Booms, Then Busts: Stellar Guidance vs Hims Undercut

Investors had little time to celebrate Eli Lilly's huge post-earnings gain. While Hims & Hers Health knocked shares down, LLY remains a healthcare stalwart.

MarketBeat

The Metabolic Split: Why Eli Lilly Soars as Novo Stumbles

Eli Lilly surges past the trillion-dollar mark as aggressive manufacturing expansion drives volume growth that eclipses rival Novo Nordisk in 2026.

MarketBeat

Wegovy and Ozempic maker forecasts sharp drop in revenue for 2026

Novo Nordisk share price plunges after blaming lower US drug prices, patent protection issues and rising competition

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

The Independent UK

Takeaways from the AP's report on turmoil surrounding the FDA's new fast-track drug program

Questions remain among top Food and Drug Administration officials over who has the appropriate legal authority to sign off on drugs cleared under a new plan to slash FDA drug review times

The Independent UK

Legal questions swirl around FDA's new expedited drug program, including who should sign off

A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations

MarketBeat

A Fresh IPO That Long-Term Investors Shouldn’t Ignore

Aktis Oncology, which recently had its IPO, has gained substantial backing from Big Pharma mainstay Eli Lilly. Investors should take note of the biotech firm.

Get all your
news in one place.

100's of premium titles.
One news app.

MarketBeat

Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns

After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.

Barchart

What to Expect From Eli Lilly’s Q4 2025 Earnings Report

Eli Lilly is gearing up to announce its fiscal 2025 fourth-quarter earnings in the near term, and analysts project its earnings to rise in double-digits.

The Independent UK

Amazon starts to offer Wegovy weight loss pill to customers

The new oral Wegovy, launched this week, contains semaglutide, the same active ingredient as injectable Wegovy and Ozempic

Fortune

The 7 most overlooked CEOs in 2025—and the 5 to watch in 2026

The Yale Chief Executive Leadership Institute highlights the top performers of 2025 and the top leaders to watch in 2026.

Evening Standard

Gemma Collins says she WILL have a baby and get married this year after showcasing 3-stone body transformation

Collins said her New Year’s champagne would be her last for a while

MarketBeat

FDA Approves Novo Nordisk's Wegovy Pill: A Game Changer for 2026

Novo Nordisk is down big in 2025, but hope is far from lost in 2026. The company's newly approved weight-loss pill could be the remedy that shares need.

International Business Times UK

Novo Nordisk's Future Vision on 'Weight Loss' Wins Scientists, Tests Wall Street's Patience

Novo Nordisk's long-term strategy for weight-loss treatments has earned praise from scientists, even as investors grow cautious about timelines, competition and near-term returns.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.